These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36369263)

  • 1. Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials.
    Chaudhary V; Sarohia GS; Phillips MR; Park D; Xie J; Zeraatkar D; Fung M; Thabane L; Loewenstein A; Holz FG; Garg SJ; Kaiser PK; Bhandari M; Guymer RH; Fraser-Bell S; Sivaprasad S; Wykoff CC
    Eye (Lond); 2023 Jul; 37(10):1966-1974. PubMed ID: 36369263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Curran K; Lucenteforte E; Peto T; Parravano M
    Cochrane Database Syst Rev; 2023 Jun; 2023(6):CD007419. PubMed ID: 38275741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007419. PubMed ID: 30325017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
    Mehta H; Hennings C; Gillies MC; Nguyen V; Campain A; Fraser-Bell S
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011599. PubMed ID: 29669176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor for diabetic macular oedema.
    Virgili G; Parravano M; Menchini F; Evans JR
    Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.
    Zhu Y; Zhang T; Xu G; Peng L
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD011160. PubMed ID: 27977064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
    Virgili G; Parravano M; Menchini F; Brunetti M
    Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monotherapy laser photocoagulation for diabetic macular oedema.
    Jorge EC; Jorge EN; Botelho M; Farat JG; Virgili G; El Dib R
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010859. PubMed ID: 30320466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT.
    Lois N; Campbell C; Waugh N; Azuara-Blanco A; Maredza M; Mistry H; McAuley D; Acharya N; Aslam TM; Bailey C; Chong V; Downey L; Eleftheriadis H; Fatum S; George S; Ghanchi F; Groppe M; Hamilton R; Menon G; Saad A; Sivaprasad S; Shiew M; Steel DH; Talks JS; Doherty P; McDowell C; Clarke M
    Health Technol Assess; 2022 Dec; 26(50):1-86. PubMed ID: 36541393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
    Shalchi Z; Mahroo O; Bunce C; Mitry D
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD009510. PubMed ID: 32633861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration.
    Sunaga T; Maeda M; Saulle R; Ng SM; Sato MT; Hasegawa T; Mason AN; Noma H; Ota E
    Cochrane Database Syst Rev; 2024 Jun; 6(6):CD015804. PubMed ID: 38829176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.
    Maturi RK; Glassman AR; Josic K; Antoszyk AN; Blodi BA; Jampol LM; Marcus DM; Martin DF; Melia M; Salehi-Had H; Stockdale CR; Punjabi OS; Sun JK;
    JAMA Ophthalmol; 2021 Jul; 139(7):701-712. PubMed ID: 33784735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aflibercept for neovascular age-related macular degeneration.
    Sarwar S; Clearfield E; Soliman MK; Sadiq MA; Baldwin AJ; Hanout M; Agarwal A; Sepah YJ; Do DV; Nguyen QD
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD011346. PubMed ID: 26857947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
    Martinez-Zapata MJ; Salvador I; Martí-Carvajal AJ; Pijoan JI; Cordero JA; Ponomarev D; Kernohan A; Solà I; Virgili G
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD008721. PubMed ID: 36939655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
    Brown DM; Wykoff CC; Boyer D; Heier JS; Clark WL; Emanuelli A; Higgins PM; Singer M; Weinreich DM; Yancopoulos GD; Berliner AJ; Chu K; Reed K; Cheng Y; Vitti R
    JAMA Ophthalmol; 2021 Sep; 139(9):946-955. PubMed ID: 34351414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal steroids for macular edema in diabetes.
    Rittiphairoj T; Mir TA; Li T; Virgili G
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
    Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
    Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional outcomes of sustained improvement on Diabetic Retinopathy Severity Scale with intravitreal aflibercept in the VISTA and VIVID trials.
    Dhoot DS; Moini H; Reed K; Du W; Vitti R; Berliner AJ; Singh RP
    Eye (Lond); 2023 Jul; 37(10):2020-2025. PubMed ID: 35440699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.